Front Row Advisors LLC Amgen Inc Transaction History

Front Row Advisors LLC

$250 Million
Q1 2025

A detailed history of Front Row Advisors LLC transactions in Amgen Inc stock. As of the latest transaction made, Front Row Advisors LLC holds 9,020 shares of AMGN stock, worth $2.65 Million. This represents 1.13% of its overall portfolio holdings.

Number of Shares

9,020

Previous 9,267 2.67%

Holding current value

$2.65 Million

Previous $2.42 Million 16.36%

% of portfolio

1.13%

Previous 0.87%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$258.59 - $327.36 $63,871 - $80,857	-247 Reduced 2.67%	9,020 $2.81 Million
Q4 2024 Feb 12, 2025	SELL	$258.78 - $328.31 $19,149 - $24,294	-74 Reduced 0.79%	9,267 $2.42 Million
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $14,850 - $16,194	-48 Reduced 0.51%	9,341 $3.01 Million
Q2 2024 Aug 15, 2024	SELL	$262.75 - $319.31 $788 - $957	-3 Reduced 0.03%	9,389 $2.93 Million
Q1 2024 May 14, 2024	BUY	$268.87 - $324.56 $20,165 - $24,342	75 Added 0.8%	9,392 $2.67 Million
Q4 2023 Feb 15, 2024	SELL	$255.7 - $288.46 $31,962 - $36,057	-125 Reduced 1.32%	9,317 $2.68 Million
Q3 2023 Nov 15, 2023	SELL	$218.65 - $271.46 $35,202 - $43,705	-161 Reduced 1.68%	9,442 $2.54 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $1,285 - $1,520	6 Added 0.06%	9,603 $2.13 Million
Q1 2023 May 22, 2023	BUY	$225.79 - $275.2 $1.64 Million - $2 Million	7,277 Added 313.66%	9,597 $2.32 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $1.7 Million - $2.08 Million	-7,540 Reduced 76.47%	2,320 $960,000
Q4 2022 Feb 15, 2023	SELL	$229.03 - $291.01 $33,209 - $42,196	-145 Reduced 1.45%	9,860 $2.59 Million
Q3 2022 Nov 15, 2022	BUY	$224.46 - $253.15 $4,489 - $5,063	20 Added 0.2%	10,005 $2.26 Million
Q2 2022 Aug 15, 2022	SELL	$230.71 - $256.74 $4,152 - $4,621	-18 Reduced 0.18%	9,985 $2.43 Million
Q1 2022 May 11, 2022	BUY	$219.27 - $242.57 $108,538 - $120,072	495 Added 5.21%	10,003 $2.42 Million
Q4 2021 Mar 09, 2022	BUY	$198.88 - $227.6 $16,904 - $19,346	85 Added 0.9%	9,508 $2.14 Million
Q3 2021 Nov 03, 2021	SELL	$212.27 - $248.7 $15,920 - $18,652	-75 Reduced 0.79%	9,423 $2 Million
Q2 2021 Aug 23, 2021	BUY	$233.58 - $259.14 $16,584 - $18,398	71 Added 0.75%	9,498 $2.13 Million
Q1 2021 Apr 28, 2021	BUY	$221.91 - $258.6 $35,505 - $41,376	160 Added 1.73%	9,427 $2.35 Million
Q4 2020 Feb 25, 2021	SELL	$216.38 - $257.67 $29,211 - $34,785	-135 Reduced 1.44%	9,267 $2.13 Million
Q3 2020 Nov 30, 2020	SELL	$234.65 - $260.95 $32,616 - $36,272	-139 Reduced 1.46%	9,402 $2.11 Million
Q2 2020 Aug 17, 2020	SELL	$197.81 - $242.74 $18,989 - $23,303	-96 Reduced 1.0%	9,541 $2.25 Million
Q1 2020 May 08, 2020	BUY	$182.24 - $241.7 $61,779 - $81,936	339 Added 3.65%	9,637 $2.31 Million
Q4 2019 Feb 14, 2020	SELL	$189.21 - $243.2 $30,273 - $38,912	-160 Reduced 1.69%	9,298 $2.24 Million
Q3 2019 Nov 08, 2019	SELL	$174.11 - $208.62 $39,174 - $46,939	-225 Reduced 2.32%	9,458 $1.83 Million
Q2 2019 Aug 27, 2019	SELL	$166.7 - $195.41 $14,002 - $16,414	-84 Reduced 0.86%	9,683 $1.78 Million
Q1 2019 May 17, 2019	SELL	$180.87 - $203.88 $75,422 - $85,017	-417 Reduced 4.09%	9,767 $1.86 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $67,256 - $78,510	377 Added 3.84%	10,184 $1.98 Million
Q3 2018 Nov 13, 2018	BUY	$185.29 - $208.89 $12,229 - $13,786	66 Added 0.68%	9,807 $1.84 Million
Q2 2018 Jul 31, 2018	BUY	$166.05 - $186.51 $27,730 - $31,147	167 Added 1.74%	9,741 $1.88 Million
Q1 2018 May 21, 2018	BUY	$169.43 - $198.0 $34,733 - $40,590	205 Added 2.19%	9,574 $1.63 Million
Q4 2017 Feb 01, 2018	BUY	$168.79 - $188.59 $1.58 Million - $1.77 Million	9,369	9,369 $1.63 Million

Others Institutions Holding AMGN

# of Institutions

3,310

Shares Held

429M

Call Options Held

8.06M

Put Options Held

7.7M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $157B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Front Row Advisors LLC with notifications on news.

Account

Front Row Advisors LLC Amgen Inc Transaction History